Teva Cited For Promo Suggesting 14-Year Old Schizophrenia Study Shows Clozapine Superiority
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Teva’s promotional piece misleadingly implies clozapine is superior to olanzapine, risperidone and haloperidol in improving one symptom cluster.
You may also be interested in...
Jazz Buys Compliance Trouble With FazaClo Acquisition
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.